0001567619-18-005081.txt : 20181105
0001567619-18-005081.hdr.sgml : 20181105
20181105161427
ACCESSION NUMBER: 0001567619-18-005081
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181101
FILED AS OF DATE: 20181105
DATE AS OF CHANGE: 20181105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McCarthy Sean A.
CENTRAL INDEX KEY: 0001654058
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 181160071
MAIL ADDRESS:
STREET 1: 343 OYSTER POINT BLVD.
STREET 2: SUITE 100
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273521219
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2018-11-01
0
0001501989
CytomX Therapeutics, Inc.
CTMX
0001654058
McCarthy Sean A.
343 OYSTER POINT BLVD.
SUITE 100
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
Common Stock
2018-11-01
4
M
0
5370
1.5749
A
87433
D
Common Stock
2018-11-01
4
S
0
100
15.005
D
87333
D
Common Stock
2018-11-01
4
S
0
5270
15
D
82063
D
Common Stock
2018-11-02
4
M
0
1156
1.5749
A
83219
D
Common Stock
2018-11-02
4
S
0
1156
15.007
D
82063
D
Stock Option (Right to Buy)
1.5749
2018-11-01
4
M
0
5370
0
D
2025-02-08
Common Stock
5370
137227
D
Stock Option (Right to Buy)
1.5749
2018-11-02
4
M
0
1156
0
D
2025-02-08
Common Stock
1156
136071
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This option vests in 48 substantially equal monthly installments starting on the last day of January 2015.
This transaction was executed in multiple trades in prices ranging from $15.00 to $15.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
/s/ Debanjan Ray, as Attorney-in-Fact for Sean A. McCarthy
2018-11-05